Dr. Wagner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1997
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1999 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors Start of enrollment: 2007 Aug 01
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
- Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia Start of enrollment: 2014 Dec 01
Publications & Presentations
PubMed
- CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.Hans Gelderblom, Albiruni A Razak, Matthew H Taylor, Todd M Bauer, Breelyn Wilky
Clinical Cancer Research. 2024-09-13 - 1 citationsDesign and Implementation of an Opt-Out, End-to-End, PreemptiveTesting Program for Patients Planned for a Systemic Fluoropyrimidine.Joseph O Jacobson, Garrett Rompelman, Angela Chen, Samantha Morrison-Ma, Lindsay Murray
JCO Oncology Practice. 2024-08-01 - Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.Gregory M Cote, Candace L Haddox, Edwin Choy, Priscilla A Merriam, Emanuele Mazzola
Clinical Cancer Research. 2024-07-01
Lectures
- ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open l...2019 ASCO Annual Meeting - 6/1/2019
- Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su)...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
A Rare Occurrence of BHD and PEComa – Perspectives from a Patient and a DoctorMarch 18th, 2022
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComaJune 4th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
